Imugene Limited (ASX:IMU) has recently announced news it has received notice that the Canadian Patent Office has issued a Grant Notice for the Company’s cancer vaccine HER-Vaxx.
- Canadian Patent Office has issued Grant Notice for Imugene’s patent application protecting its cancer vaccine “HER-Vax”
- Patent will protect specific cancer vaccine formulations of commercial interest
HER-Vaxx works by targeting the same receptor as Herceptin and Perjeta, two of the leading drugs on the market, with annual sales of US$8.2 billion. The mechanism of action for HER-Vaxx may help generate improved efficacy over existing treatments and at a lower cost.